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ORIGINAL RESEARCH 
Androgenic-Anabolic Steroid-Induced 
Body Changes in Strength Athletes 
Fred Hartgens, MD; Wouter D. Van Marken Lichtenbelt, PhD; Spike Ebbing, MSc; 
Niels Vollaard, MSc; Gerard Rietjens, MSc; Harm Kuipers, MD, PhD 
BACKGROUND: Some strength athletes use androgenic-anabolic steroids (AAS) to improve body dimensions, 
though the drugs' long- and short-term effects have not been definitively established. 
OBJECTIVE: This study sought to investigate the short- and long-term effects of AAS self-administration on body 
dimensions and total and regional body composition. 
DESIGN: This prospective, unblinded study involved 35 experienced male strength athletes: 19 AAS users (drugs 
were self-administered) and 16 non user controls engaged in their usual training regimens. At baseline, 8 weeks, 
and 6 weeks after AAS withdrawal (for AAS users) circumferences were measured at 10 sites, and skinfolds 
measured at 8 sites. To assess differences in AAS regimens, 9 subjects took AAS for 8 weeks (short-AAS) and 
10 athletes took PAS for 12 to 16 weeks (long-AAS). Body composition and anthropometry were assessed at 
baseline, at the end of AAS use, and 6 weeks later. Lean body mass (LBM) was calculated from body weight and 
percentage fat. Total and regional body composition was measured by dual-energy x-ray absorptiometry. 
RESULTS: AAS use increased users' body weight by 4.4 kg and LBM by 4.5 kg, and produced increases in 
several circumferences. Percentage of fat decreased (17 .0% to 16.0% ), but fat mass remained unchanged. 
Changes persisted 6 weeks after drug withdrawal but were not less than those taken at 8 weeks. Bone-free lean 
mass of all regional body parts increased in subjects taking AAS, but fat mass was unaffected. Short- and 
long-term AAS users did not differ in any parameter measured at 8 weeks or after drug withdrawal. 
CONCLUSION: In AAS users, 8 weeks of self-administered AAS increased body weight, lean body mass, and limb 
circumferences, but decreased percentage fat compared with controls. Changes remained 6 weeks after drug 
withdrawal, though for some measurements only partially. AAS stimulated the bone-free lean mass of all body 
parts, but it did not affect fat mass. Short-term and long-term AAS administration produced comparable effects. 
T he use of androgenic-anabolic steroids (MS) in athletes seems to be widespread. As reported by 
laboratories accredited by the International Olympic 
Committee,' these drugs have been the most frequently 
detected substances in urine samples of athletes. MS 
use by elite athletes is of great concern for national and 
international sports federations because the drugs give 
users an unfair advantage and produce potentially dele-
terious health effects.2•3 MS use is not limited to elite 
For CME, see www.physsportsmed.com/cme.htm 
beginning in February 2001 
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athletes, however, and may be more extensive among 
recreational and amateur strength athletes, even though 
the media devote less attention to use in these groups. 
Strength athletes often progress to self-administra-
tion of AAS to increase muscle mass and strength. 
Weight lifters and power lifters strive primarily for 
strength, whereas bodybuilders train for optimal 
muscle mass and body dimensions.' Consequently, in 
all strength athletes increased muscle mass is desir-
able. Only a few studies have investigated the effects 
of MS on muscle mass and body dimensions. Unfor-
tunately, data are equivocal, and many questions re-




Our study sought answers to three 
questions: (1) Which body measure-
ments and composition are altered in 
strength athletes when they use sev-
eral AAS simultaneously? (2) Does 
self-administration of AAS exert dis-
tinct effects on the separate compo-
nents of regional body composition? 
and (3) What impact does the dura-
tion of AAS use have on anthropome-
try and body composition? 






AAS (n = 19) Controls (n = 16) 
32.8 ± 5.3 
177 ± 7 
88.5 ± 11.2 
19.4 ± 3.6 
Training history (yr) 
Training regimen (hr/wk) 
31.3 ± 7.0 
176 ± 9 
84.0 ± 9.9 
17.0 ± 5.7 
10.0 ± 7.3 
8.8 ± 2.5 
8.8 ± 3.6 
8.2 ± 2.3 
Values are expressed as the mean± standard deviation; AAS =androgenic-anabolic steroid 
Methods 
Subjects and their AAS use. Strength athletes were 
recruited with advertisements at local gyms. Inclusion 
criteria were: male, at least 3 years of strength training 
experience, and age between 20 and 45 years. Candi-
dates excluded were those who smoked or had hyper-
tension, diabetes mellitus, liver disease or abnormal liv-
er enzyme levels, hereditary hypercholesterolemia, 
elevated serum cholesterol levels (>6.5 mrnol/L), or in-
fertility. Before participating, all subjects completed a 
questionnaire containing questions about medical his-
tory, health status, training experience and status, nu-
trition, nutritional supplement use, and AAS use. 
After the initial screening, each strength athlete under-
went a full medical examination by a physician for evalu-
ation of health status and to screen for possible missed 
exclusion criteria During the examination, we provided 
extensive oral and written information about the study to 
each subject. All subjects signed an informed consent 
form approved by the Ethical Committee of Maastricht 
Dr Hartgens is research and science coordinator at The Netherlands' Center 
for Doping Affairs in Capelle aan den IJssel, The Netherlands. Or Van Marken 
Lichtenbelt is assistant professor in the department of human biology at Maas-
tricht University, Mr Ebbing and Mr Vollaard were Masters students at The 
Netherlands Center for Doping Affairs in Capelle aan den IJssel. Mr Rietjens is 
assistant research and science coordinator at The Netherlands Center for Doping 
Affairs in Capelle aan den IJssel and a doctoral candidate in the department of 
movement sciences at Maastricht University, Maastricht, The Netherlands. Dr 
Kuipers is head of the department of movement sciences at Maastricht University. 
Address correspondence to Fred Hartgens, MD, The Netherlands Centre 
for Doping Affairs, PO Box 5014, 2900 EA Capelle aan den IJssel, The 
Netherlands; e-mail to fred.hartgens@necedo.ni. 
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University (Maastricht, The Netherlands). 
Thirty-five strength athletes participated in this 
study. Most athletes (28) performed strength training 
mainly for esthetic purposes and characterized their 
training regimen as bodybuilding training; only 7 of 
these subjects participated in bodybuilding contests. 
Seven participants were competitors: 3 engaged in 
strength training as a part of their boxing training in 
addition to using AAS for esthetic reasons, and 4 ath-
letes were principally involved in resistance training 
for powerlifting competition. 
Among the subjects, 19 had decided to begin using 
AAS to supplement their regular strength training regi-
men (AAS group). The remaining 16 volunteers who 
had not used nor were willing to take AAS served as con-
trols (CO group). The physical and training characteris-
tics of both groups are presented in table 1. 
Assessing AAS status. Before entering the study, 
AAS group members were expected not to have used 
AAS for at least the previous 3 months. This was veri-
fied from information that each subject provided and 
was corroborated by urinalysis before the start of the 
study. Interviews revealed that AAS subjects had been 
drug-free for 8.1 ± 6.4 months (range, 3 to 30 months). 
All but l of the AAS group had previously used AAS. 
The average participant had started using AAS 4.8 
years (range, l to 14 years) before the study, and the 
mean number of AAS cycles self-administered was 7.1 
(range, l to 30 cycles). 
Study disclaimer. Although several subjects had re-
ceived a prescription for steroids from a physician, 
most AAS users bought the drugs on the black market. 
Users devised MS regimens based on information 
provided by other strength athletes and on their own 
53 
(i!Ji@i@j continued 
TABLE 2. Subjects and Duration, Route, and Total of Androgenic-Anabolic Steroids Used 
ID Number AAS Duration (wk) Drug (route) Total Used* 
1. BC101 16 
2.SS102 16 
3. MB108 8 
4. JD111 12 
5.ES112 16 
stanozolol (im) 
nandrolone decanoate (im) 










--·-·----~------··· -- .... -~----~,_ ___ ' -·--~ ---- --·- .. ~--~-~ 
nandrolone decanoate (im) 
trenbolone acetate (im) 
methandrostenolone (po) 
chorionic gonadotropin (im) ---------- --- ---- ---- --------------
testosterone enanthate (im) 
stanozolol (im) 























stanozolol (im) 750 mg 
stanozolol (po) 450 mg 
testosterone propionate (im) 375 mg 
nandrolone decanoate (im) 875 mg 
metenolone (im) 300 mg ----·------·-----·------········· - ........................ ______ ..... , .. _______ .. __ 





nandrolone decanoate (im) 
drostanolone (im) 
~---·-,-- -~ _,.- ..... ··~·-·"-··---- -~ .. ---· 
clenbuterol (po) 
stanozolol (po) 
nandrolone decanoate (im) 
stanozolol (po) 
stanozolol (im) 
trenbolone acetate (im) 
chorionic gonadotropin (im) 
testosterone undecanoate (1m) 
tamoxifen (po) 
nandrolone decanoate (im) 
stanozolol (im) 
chorionic gonadotropin (im) 
stanozolol (po) 
methandrostenolone (po) 
testosterone heptilate (im) 






of these but 













I ID Number AAS Duration (wk) 
10. GR124 8 
11. PW125 8 
-·------------
12. MD139 12 
13. CL148 8 
~---~----------
14.FL151 12 





insights and beliefs. Table 2 presents the details of MS 
use in participants. Readers should note that the inves-
tigators did not provide MS, that researchers did not at-
tempt to influence which MS was used, and the re-
searchers did not have any role in MS administration. 
that was divided in three experiments to investigate 
the objectives set (figure 1). 
Study design. We conducted a nonblinded study 
54 
Experiment 1: Total body composition and anthro-
pometry. Experiment 1 was designed to investigate 
changes of body composition and anthropometric 
measurements in strength athletes induced by self-ad-
Vol 29 • No. 1 • January 2001 e THE PHYSICIAN AND SPORTSMEDICINE 
Drug (route) Total Used* 
methandrostenolone (po) 560mg 
mesterolone (po) 1,400 mg 
metenolone Jim) 800mg 
nandrolone ecanoate (im) 400mg 
testosterone (phenyl-) propionate 
isohexanoate (im) 1,750 mg 
trenbolone acetate (im) 602 mg 
stanozolol (im) 250mg 
boldenone (im) 300mg 
stanozolol (po) 420mg 
mesterolone (po) 5,600 mg 
metenolone (im) 1,600 mg 
oxymetholone (po) 3,500 mg 
nandrolone decanoate (im) 1,625 mg 
nandrolone decanoate (im) 2,600 mg 
stanozolol ~po l 1,036 mg 
stanozolol im 850 mg 
testosterone enanthate (im) 3,750 mg 
testosterone cypionate (im) 5,000 mg 
chorionic gonadotropin (im) 4,500 IU 
methandrostenolone (po) 980mg 
testosterone cypionate (im) 750 mg 
trenbolone acetate (im) 880 mg 
chorionic gonadotropin (im) 4,500 IU 
methandrostenolone (po) 1,115 mg 
metenolone (po) 1,850 mg 
mesterolone (po) 675mg 
stanozolol (po) 2,170 mg 
oxymetholone (po) 1,225 mg 
nandrolone decanoate (im) 4,400 mg 
clenbuterol (po) 1.68 mg 
testosterone enanthate (im) 2,500 mg 
testosterone cypionate (im) 1,000 mg 
drostanolone (im) 300 mg 
tanozolol (im) 1,200 mg 
stanozolol (im) 1,150 mg 
testosterone (im) 5,500 mg 
clenbuterol {po l 1 mg 
oxymetholone po) 1,900 mg 
chorionic gonadotropin (im) 1,500 IU 
tamoxifen (po) 440mg 
ministered MS. Body composition and dimensions 
were assessed by taking skinfold thicknesses and cir-
cumferences, respectively. Measurements were taken 
before the start of MS use {baseline) and after 8 weeks 
of MS use. In all MS users, measurements were also 
tak~n 6 weeks after drug cessation, regardless of the 
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length of MS self-administration. In controls, the 
same measurements were done at the start of the 
study and after 8 weeks of strength training. 
Experiment 2: Regional alterations of body compo-
sition. Eleven strength athletes (6 MS, 5 CO) from ex-
periment 1 were randomly selected to participate in 
experiment 2. Subjects' body composition was deter-
mined with dual-energy x-ray absorptiometry 
(DEXA), in addition to the regular body composition 
and anthropometric measurements taken in experi-
ment 1. In 6 strength athletes, we performed DEXA 
measurements at baseline and after 8 weeks of MS 
self-administration. In 5 controls, body composition 
measurements by DEXA were carried out only at the 
start of the study. 
Experiment 3: Impact of duration of MS self-admin-
istration. Before the start of the study we divided the 
MS users from experiment 1 into two subgroups based 
on their intended MS course duration. Nine subjects 
had decided to take these drugs for 8 weeks (short-
MS), while the remaining 10 athletes intended to use 
MS for 12 to 16 weeks {long-MS). Anthropometric 
measurements and determination of body composi-
tion were carried out at baseline, at the end of the drug 
administration, and 6 weeks after MS withdrawal. 
Measurements. Height was measured with an an-
thropometer. Body weight was determined to the 
nearest 0.1 kg using a bascule. 
Skinfolds were measured with a Holtain caliper at 
eight sites: biceps, triceps, subscapular, pectoral, 
suprailiac, umbilicus, thigh, and calf. All measurements 
were taken twice by an experienced investigator. The 
mean of both measurements was recorded. To avoid 
interobserver error, a single investigator took measure-
ments in the same subject throughout the study. The 
percentage of fat was estimated from skinfold mea-
surements according to the method of Dumin and 
Wormersley.4 Lean body mass and fat mass were calcu-
lated using body weight and percentage fat. 
Eleven circumference measurements at 10 sites were 
taken with a tape measure: neck, thorax, waist, but-
tacks, upper arm (relaxed), upper arm (contracted), 
forearm, wrist, thigh Uust below the buttocks), thigh 
(two-thirds the distance from the major trochanter 
and lateral site of the knee joint), and calf. An experi-
enced investigator took all measurements twice, and 




Experiment 1: Total body composition and anthropometry. 
Subjects: 19 AAS users (9 subjects administered 8 weeks AAS and 10 subjects used for 12-16 weeks) and 16 nonusers. 
AAS use for 
8 weeks 






+ End of AAS use 
(= 8 weeks) 
// 
+ 8 weeks 
AAS use 
+ 8 weeks 
end of 
AAS use 
+ 6 weeks after withdrawal 
(= 14 weeks) 
+ 6 weeks after 
withdrawal 
Experiment 2: Regional alterations of body composition (DEXA measurements). 
Subjects: 6 AAS users and 5 non users. (DEXA measurements done in controls at baseline only.) 
AAS users 
+ Baseline 
Experiment 3: Impact duration AAS sell-administration. 





+ End of AAS use 
after 8 weeks 
+ 8 weeks AAS use 
+ 6 weeks after 
withdrawal 
+ + 
End of AAS use 6 weeks after 
after 12-16 weeks withdrawal 
FIGURE 1. Overview of the experiments of AAS use and body changes. 
~ = indicates measurement; 11= indicates that the duration of AAS sell-administration varied between subjects from 12 to 16 weeks; 
AAS =androgenic-anabolic steroids; DEXA =dual energy x-ray absorptiometry 
Total and regional body composition measurements 
were performed using DEXA apparatus (DPX-L, Lunar 
Carp, Madison, Wisconsin) at a fast scan speed with a 
whole-body resolution of 4.8 x 9.6 mm. To determine 
the composition of regional body segments and limbs, 
DEXA measurements were divided in discrete values 
56 
for arms, legs, and trunk on the basis of anatomic land-
marks. As determined by Mazess et al,S the precision of 
these measurements is 1.5% for the arms, 0.8% for the 
legs, and 1.1% for the trunk. Total mass, fat mass, and 
bone-free lean mass were determined using Lunar 
software (version 1.3 z) for each body region (arms, 
continued 
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trunk, and legs). 
Monitoring and compli-
ance. Information about the 
subjects' training and nutri-
tional habits was collected 
before the start of the study 
and in week 8. Subjects' nu-
tritional intake was deter-
mined with a 3-day diary. 
Training data were obtained 
by a 1-week log. For long-
MS strength athletes, nutri-
tional and training data were 
also obtained at the end of 
the MS administration. In 
all MS users, these data were 
collected 6 weeks after drug 
cessation. 
To gauge subjects' compli-
ance with drug administra-
tion or abstinence before the 
start of the study and after 
8 weeks, urine samples from 
all athletes were obtained for 
drug evaluation purposes 
(Netherlands Institute for 
Drug and Doping Research, 
Utrecht, The Netherlands). 
For the long-MS group, urine 
samples were taken at the 
end of the drug-use period. 
All MS-using strength ath-
letes submitted urine sam-
ples 6 weeks after drug with-
drawal. From all samples 
taken, about one-third were 
randomly chosen for analysis. 
Statistical analysis. De-






Upper arm (relaxed) 






























39.2 ± 1.9 
39.6 ± 2.2 
95.8 ± 6.5 
98.5 ± 7.3 
84.8±7.1 
86.8 ± 5.4 
98.7 ± 5.6 
99.3 ± 4.8 
36.6 ± 3.0 
38.9 ± 3.7 
40.1 ± 3.3 
42.0 ± 3.6 
31.3 ± 1.9 
32.8 ± 2.8 
18.2 ± 1.0 
18.3 ± 0.8 
61.5 ± 5.5 
63.4 ± 4.6 
50.0 ± 3.4 
51.8±3.3 
38.7 ± 2.2 
40.2 ± 2.6 
6Wk 
8Wk Postwithdrawal 
40.5 ± 2.1 ### 40.2 ± 1.9 * * 
39.6 ± 2.2 na 
98.4 ± 6.4 98.1 ± 6.5 * * 
99.9 ± 7.2 na 
86.3±7.1 85.1 ± 7.2 
87.1 ± 6.4 na 
100.6 ± 5.5 100.0±5.5** 
100.0 ± 4.9 na 
38.5 ± 3.3 ### 37.8 ± 3.4 ** 
39.0 ± 3.8 na 
41.6±3.1## 41.5 ± 3.5 *** 
42.4 ± 3.7 na 
32.4 ± 2.1 ### 32.6 ± 2.8 ** 
32.7 ± 2.2 na 
18.5±1.1# 18.3 ± 1.0 
18.3 ± 0.9 na 
63.7 ± 5.1 ## 62.7 ± 5.1 * 
63.4 ± 4.8 na 
52.2 ± 4.4 ## 50.8 ± 3.6* 
51.6 ± 2.9 na 
39.6 ± 2.2 ### 39.1 ± 2.2* 
40.2 ± 2.7 na 
All values are expressed in grams as the mean ±standard deviation. Mann Whitney test for interaction 
was used to test interaction, the difference between change in control group and AAS group;#= P< 
0.05; ## = P< 0.01; ### = P< 0.001. 
Wilcoxon test was used to compare differences between postwithdrawal and baseline; * = P< 0.05; * * = 
P< 0.01; *** = P< 0.001. 
scriptive statistics were calcu- AAS =androgenic-anabolic steroid; na =data not available 
lated for all measurements 
using Stat-View software (Abacus Concepts, Berkeley, 
California, 1994). Data are presented as mean plus or 
minus standard deviation (SD). The Mann-Whitney 
U-test was used to compare differences in the ob-
served changes between groups. The Wilcoxon signed 
rank test was used for analysis of intragroup changes 
after drug withdrawal (experiment 1) and for DEXA 
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measurements of subjects taking MS (experiment 2). 
The level of significance was set at 0.05 for all analyses. 
Results 
Total body composition and anthropometry. After 
8 weeks, the MS group had a significant increase of 




TABLE 4. Analysis of the Effects of AAS Use on Regional Body Mass 
were not significantly differ-
ent between the MS users 
and control athletes. After 8 
weeks of AAS use, the 
weight of the arm was sig-
nificantly increased, but 
the weight of the trunk and 
legs remained unchanged. 
Bone-free lean masses of 
the arms, trunk, and legs 
were significantly greater 
during AAS use than at 
baseline (table 4). MS use 
did not affect the fat mass of 
the arms, legs, and trunk. 
Total bone mineral density 
and bone mineral content 
did not change significantly. 
Region and Segment Control AAS Group, AAS Group, Difference, 
Group (g) Baseline (g) 8 Wk (g) Baseline vs 8 Wk (g) 
Arms: Total mass 10,013 10,470 11,320 0.028 
±1 ,993 ±1 ,723 ± 1,910 
Fat mass 1,370 1,721 1,317 ns 
±838 ±1 ,240 ±828 
Bone-free lean mass 8,642 8,750 10,004 0.03 
±1 ,296 ±1 ,066 ± 1 '129 
Legs: Total mass 25,699 24,228 25,390 ns 
±4,866 ±3,390 ±2,768 
Fat mass 4,649 3,785 3,605 ns 
± 1,755 ±1 ,600 ± 1 '1 01 
Bone-free lean mass 21,050 20,443 21,785 0.03 
±3,443 ±2,436 ±2,134 
Trunk: Total mass 35,762 37,798 39,375 ns 
±4,269 ±4,845 ±4,372 
Length of AAS regimen. Fat mass 6,824 7,073 6,490 ns 
±1,778 ±3, 119 ±2,670 
Bone-free lean mass 28,938 30,725 32,885 0.046 
±3,257 ±2,602 ±1 ,936 
All values are expressed in grams as the mean ± standard deviation. Paired AAS group data were 
analyzed using the Wilcoxon signed rank test at 0.05 significance. 
No significant differences 
were observed in body 
weight, percentage of fat, 
fat mass, lean body mass, 
and circumferences be-
AAS =androgenic-anabolic steroid; ns = not significant 
mass, whereas the controls exhibited no significant 
change. Mean body weight increased from 84.0 ± 9.9 to 
88.4 ± 10.7 kg, and lean body mass rose from 69.6 kg to 
7 4.1 kg. The percentage of fat during MS use was sig-
nificantly reduced from 17.0% to 16.0%, but this was 
not reflected in a loss of fat mass. Gains in body weight 
and lean body mass were still partly present 6 weeks 
after drug withdrawal (table 3). In both groups, no sig-
nificant increase in sk.infold measurements or their 
sums were observed during the study. 
In the MS group, increases in the circumferences 
of neck, upper arm, forearm, wrist, thigh, and lower leg 
were significantly larger than in the control group. Cir-
cumference changes of the thorax, waist, and buttocks 
did not reach significance compared with those of 
controls. Although the circumferences were slightly re-
duced after drug withdrawal, they were still increased 
compared with baseline levels (see table 3). 
Regional body composition changes. Baseline 
DEXA measurements of body segment composition 
60 
tween short-MS and long-
MS users. Similarly, these 
parameters were not sig-
nificantly different between groups 6 weeks after 
drug withdrawal . 
Training, nutrition, and compliance. Throughout 
the entire study, weekly training hours and regimens be-
tween groups in the three experiments remained com-
parable. The same was true for nutritional intake. Uri-
nalysis revealed compliance within the groups: Urine 
samples from the MS users contained steroid metabo-
lites, and samples of the CO group did not. 
Discussion 
AAS-induced changes. Experienced strength ath-
letes who use a self-composed course of MS for 
8 weeks exhibited increased total body weight and to-
tal lean body mass compared with those who did 
strength training alone; total fat mass remained unaf-
fected. Among regional body segments (arms, legs, 
and trunk) in these athletes, only arm weight in-
creased significantly. However, lean mass was signifi-
cantly increased in all regional body parts, and these 
Vol 29 • No. 1 • January 2001 • THE PHYSICIAN AND SPORTSMEDICINE 
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findings are reflected in the increased arm and leg cir-
cumferences. Increases were for the most part still 
present 6 weeks after drug cessation. These findings 
are relevant because until now scientific data con-
cerning AAS effects on anthropometry and body 
composition were equivocal. 
From cross-sectional studies, one might infer that 
AAS-using strength athletes differ in body composition 
from nonusing athletes."·' These observations have 
been supported by longitudinal studies. The most pro-
nounced effects on body weight and lean body mass 
were found in athletes who self-administered several 
AAS simultaneously in high doses.•·• Such regimens 
may increase body weight by an average of about 
5.2 kg (ll.4lb). Lean body mass increases may be even 
larger, especially after long-term administration."·10 
The present study indicates that the use of a single 
AAS seems to induce less remarkable effects than mul-
tiple-drug regimens."- 11 -13 This is in line with an observa-
tion of Forbes, 1' who had previously described a posi-
tive relationship between the total dose of AAS used 
and the increase oflean body mass. On the other hand, 
research9,11Is.Ifi that compared the effects of different 
doses of a single AAS indicates that such a relationship 
might be less ambiguous than that proposed by Forbes. 
Previous methods and DEXA. One factor that may 
have contributed to the consistent results is the 
method used to determine body composition. No al-
terations were seen in studies17-20 that investigated body 
composition with underwater weighing. In these stud-
ies, the effect of a single drug was analyzed, but, 
unfortunately, no reports are available on underwater 
weighing assessment of body composition in multiple-
drug-using athletes. Although previous studies as-
sessed the traditional two-compartment model either 
with skinfold measurements or with underwater 
weighing, our study employed DEXA to assess a three-
compartment model for body composition alterations. 
DEXA was designed primarily to estimate bone 
mineral content and density in humans.21 Determina-
tion of body composition by DEXA is based on the dif-
ference in attenuation ofx-rays between soft and bone 
tissue as well as the difference in attenuation between 
fat and lean tissue. This method provides a three-com-
partment model that divides the body into total bone 
mineral content, bone-free lean mass, and fat mass. 
An advantage of DEXA over hydrodensitometry is that 
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DEXA appears to be less affected by hydration sta-
tus.21.'' This may be an important advantage in esti-
mating body composition in athletes since hydration 
status may be affected by training. 
Assessing regional body changes. Because of the 
documented DEXA accuracy for total and regional 
body dimension measurement5·23 and the AAS poten-
tial for inducing regional changes in body composi-
tion, strength athletes may have particular interest in 
both DEXA and AAS. DEXA measurements in this 
study reveal an increase in bone-free lean mass of all 
body parts measured in bodybuilders using AAS. One 
interesting finding was that the increase in the bone-
free mass of the arms was approximately twice that in 
the leg or trunk (14% versus about 7%). This finding 
could not be attributed to differences in training regi-
mens because the training diaries revealed compara-
ble regimens in both groups. On the other hand, in an-
other study16 the administration a single anabolic 
steroid (nandrolone decanoate) induced the largest 
gain of bone-free lean mass in the legs and trunk. 
Since both studies are complementary, one possibility 
might be that different AAS regimens may affect spe-
cific areas more than others. 
Although evidence has shown that AAS increases 
lean body mass,24-26 no one has determined what con-
stitutes the change in lean mass. Previous research as-
sociated AAS-induced lean body mass alterations with 
increments of blood volume and water retention.1w.zs 
In a recent study (W Van Marken Lichtenbelt etal, 
manuscript submitted for publication), we were able 
to investigate the effects of AAS on body composition 
with a four-compartment model. That study revealed 
that total body water increased from AAS use but that 
the ratio between extracellular and intracellular water 
remained unaffected. In addition, lean mass hydration 
status was not influenced by AAS. Thus, the most likely 
explanation for the gain oflean mass can be explained 
by muscle increase rather than from water retention. 
Dispelling steroid-use myths. Among strength ath-
letes, long-term AAS administration is generally be-
lieved to produce better results than short-term use. 
Additionally, these athletes claim that after long-term 
AAS use the gains in body composition parameters 
will persist longer than after short-term administra-
tion. These beliefs are not supported by the present 




metric variables after short- and long-term MS use 
were comparable. The same applied for residual 
changes seen after drug withdrawal. Therefore, we 
conclude that duration of MS administration in itself 
is not the key factor for optimal and longstanding ef-
fects on body composition. 
Health hazards. From a medical point of view, 
long-term MS administration is of great concern.'• 
Several investigators•·30•31 have reported that MS use in-
duces an unfavorable lipoprotein profile and thus in-
creases the risk for cardiovascular diseases. Recent re-
search has demonstrated that duration of MS use has 
a strong impact on the lipoprotein profile changes.33 
Extended MS administration provokes more dramatic 
side effects on the lipoprotein profile compared with 
short-term MS use, and the time required for full re-
versal of these side effects was prolonged after long-
term use (E Hartgens et al, manuscript submitted for 
publication). Consequently, long-term users are more 
prone to have cardiovascular events. 
Most strength athletes are convinced that after drug 
abstinence the effects on body composition will persist 
for some time. Our results show that 6 weeks after drug 
withdrawal the changes of circumferences were still 
significantly increased over baseline values, though 
slight decreases were seen compared with values at the 
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transplant fractures continued from page 40 
The level of performance is also affected by the par-
ticular kind of grafting. Most kidney and liver trans-
plant recipients are able to regain their former physical 
condition, but this is not true for heart and lung trans-
plant subjects. The latter continue to be affected by 
heart denervation and altered lung function, which of-
ten keeps them out of competition. 
Recommendations 
Preventive medical therapy and follow-up measures 
as well as sport -specific recommendations are needed 
to allow transplant patients safe athletic participation. 
Until reliable clinical and epidemiologic studies are 
performed, low-impact, recreational, noncontact 
sports are recommended, and high-level competition 
by transplant patients should be discouraged. AN 
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